Table of Contents
Tumours disappear in all participants of small cancer drug trial. Bowel cancer, also known as colorectal cancer, is the second most frequent cancer in both women and men and the third most prevalent cancer overall.
Tumours disappear in all participants of small cancer drug trial. Now, a modest medication trial for rectal cancer in the United States has produced results that are incredibly encouraging: tumors were discovered to have vanished in every participant.
What exactly is colon cancer?
A condition known as colorectal cancer (CRC) is characterized by uncontrolled cell growth in the colon or rectum. It is also known as colon cancer informally. The large intestine, or colon, is the large bowel. The rectum serves as the conduit between the colon and the anus.
CRC signs and symptoms include:
A reoccurring modification to bowel behavior
Bleeding in the stools or from the rear passage
Unexplained weight loss or tiredness
Unexplained abdominal pain
Any new lumps, swellings, or masses in the abdomen
Anyone experiencing any of these symptoms should speak with a healthcare professional. It may not be anything serious, but if it is cancer, finding it early dramatically improves the chances of getting better.
There were more than 1.9 million new cases of CRC in 2020. The global burden of CRC is expected to increase by 60 percent to more than 2.2 million new cases and 1.1 million deaths by 2030.
The treatment for those diagnosed with colorectal cancer usually involves:
Surgery: the cancerous segment of the bowel is cut out; this is the most effective way of curing bowel cancer
Chemotherapy: medicines to kill cancer cells
Radiotherapy: using radiation to kill cancer cells
Due to the sheer numbers being diagnosed with this disease globally, and the burden it puts on patients and healthcare systems, we urgently need new effective and safe treatments to be made available.
What does the most recent study reveal?
The latest study, which was released in June’s issue of the New England Journal of Medicine, has scientists and medical experts buzzing. The study, conducted at the Memorial Sloan Kettering Cancer Center in New York, examined 12 patients who were prescribed the new medication, dostarlimab, created by the pharmaceutical corporation GlaxoSmithKline, and who had a particular type of rectal cancer.
Patients received the medication every three to six months, costing $11,000 per dose. Standard chemo, radiation, and surgical procedures were also performed on some of the patients, but for those who responded favorably to the medication, this step may be bypassed.
All 12 patients were discovered to be in remission at the conclusion of their treatment, and physical examinations and scans revealed no signs of cancer.
Specific mismatch repair deficient (MMRd) locally advanced rectal cancer was the type of cancer being treated. Mismatch repair genes play a role in repairing errors that occur during DNA replication in cells. DNA mutations can occur and cause cancer when they are insufficient, as is the situation with these tumors.
The medication class known as anti-programmed death-1 (anti-PD1) monoclonal antibodies includes dostarlimab. Rectal tumor cells in particular have unique immunosuppressive traits known as programmed death-1 (PD-1), which inhibit the production of T-cells, which are essential for their destruction. Dostarlimab, an anti-PD1 medication, prevents this action from taking place, allowing the immune system to target and kill the cancer cells because they are unable to defend themselves from the T-cells.
The current study moves us one step closer to individualizing care for each patient according to their tumor, which is the ultimate goal of cancer treatment. By administering medications that are specific to that person’s cancer, each person’s cancer will have tiny variations in the types of mutations the cancer cells have.
How may colorectal cancer risk be decreased?
People should never be made to feel guilty for receiving a cancer diagnosis of any kind; this is never their fault. A healthcare team should regularly monitor you if you have a strong family history of colorectal cancer because unavoidable factors like genetics frequently play a significant role. People should be especially watchful for any new and unexplained symptoms as they may indicate a higher risk of CRC if they also have other bowel issues, such as inflammatory bowel disease.
We can all take steps to lower our risk of CRC, though. We should attempt to limit our intake of red and processed meat, including beef, lamb, hog, and goat, to one to two meals per week because there is evidence that it may raise the risk of colon cancer. We should consume about 30 grams of fiber each day, which includes whole grains, oats, chickpeas, lentils, and beans. This has been demonstrated to lower our risk of colon cancer.
Maintaining a healthy weight will lower our risk of getting colon cancer because obesity has been associated with the disease. Bowel cancer is less likely to strike those who exercise regularly. Make sure you only consume alcohol at safe levels and have at least two days per week without alcohol because alcohol has been related to seven different types of cancer, including bowel cancer. Bowel cancer has also been related to smoking, therefore quitting will lower your chance of both this cancer and a number of other illnesses.
There are now screening programs in place in several nations to aid in the early detection of bowel cancer before symptoms appear. Please take advantage of any tests provided to you as part of screening programs, including those that may need you to submit a stool sample. Your chances of survival are improved the earlier these things are discovered.
Finally, never be ashamed to discuss your bowel habits with a medical expert because we are used to it and need to know if they have changed. It might not be something dangerous, but it is best to be aware of it sooner rather than later.
